Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting
Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation, and Degeneration 2021 conference on February 13, 2021 Clearside Biomedical, Inc. , a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of … – Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders – – CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation, and Degeneration 2021 conference on February 13, 2021 –
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of th